Novel Quinazoline-Based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity
Open Access
- 1 December 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (23), 11344-11352
- https://doi.org/10.1158/0008-5472.can-07-1662
Abstract
Previous evidence showed the ability of the quinazoline-based α1-adrenoreceptor antagonist doxazosin to suppress prostate tumor growth via apoptosis. In this study, we carried out structural optimization of the chemical nucleus of doxazosin and a subsequent structure-function analysis toward the development of a novel class of apoptosis-inducing and angiogenesis-targeting agents. Our lead compound, DZ-50, was effective at reducing endothelial cell viability via a nonapoptotic mechanism. Treatment with DZ-50 effectively prevented in vitro tube formation and in vivo chorioallantoic membrane vessel development. Confocal microscopy revealed a significantly reduced ability of tumor cells to attach to extracellular matrix and migrate through endothelial cells in the presence of DZ-50. In vivo tumorigenicty studies using two androgen-independent human prostate cancer xenografts, PC-3 and DU-145, showed that DZ-50 treatment leads to significant suppression of tumorigenic growth. Exposure to the drug at the time of tumor cell inoculation led to prevention of prostate cancer initiation. Furthermore, DZ-50 resulted in a reduced formation of prostate-tumor derived metastatic lesions to the lungs in an in vivo spontaneous metastasis assay. Thus, our drug discovery approach led to the development of a class of lead (quinazoline-based) compounds with higher potency than doxazosin in suppressing prostate growth by targeting tissue vascularity. This new class of quinazoline-based compounds provides considerable promise as antitumor drugs for the treatment of advanced prostate cancer. [Cancer Res 2007;67(23):11344–52]Keywords
Other Versions
This publication has 36 references indexed in Scilit:
- Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort StudyJournal of Urology, 2007
- Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a Death Receptor–Mediated PathwayCancer Research, 2006
- Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis?Cancer Research, 2005
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Bromodeoxyuridine Induces Integrin Expression at Transcriptional (α2Subunit) and Post-Transcriptional (β1Subunit) Levels, and Alters the Adhesive Properties of Two Human Lung Tumour Cell LinesCell Communication & Adhesion, 2001
- A Mechanism for Modulation of Cellular Responses to VEGF Activation of the IntegrinsMolecular Cell, 2000
- alpha 1-ADRENOCEPTOR ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 1999
- Intratumoral vascularity as a prognostic factor in cancers of the urogenital tractEuropean Journal Of Cancer, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Disruption of epithelial cell-matrix interactions induces apoptosisThe Journal of cell biology, 1994